Latest Regulatory Reform News

Chorus Limited has reported a strong half-year performance driven by fibre broadband growth, operational efficiencies, and a return to profitability, while launching initiatives to boost digital inclusion.

Challenger Limited reported a solid first half of FY26 with a 2% rise in normalised net profit after tax and record annuity sales. The company also announced a $150 million on-market share buy-back, reflecting confidence in its strong capital position.

WT Financial Group Limited has reported a robust 16.1% increase in net revenue for the half-year ending December 2025, underpinned by strategic acquisitions and a pioneering joint venture. The company’s proprietary AI technology and industry consolidation efforts position it well for continued expansion.

Ryman Healthcare has unveiled a refreshed strategy focused on growing recurring earnings and optimising its portfolio, targeting a $150 million sustainable cash flow improvement and $500 million cash release by FY29. The company plans to resume dividends from FY28, underpinned by a resilient balance sheet and disciplined capital management.

Avecho Biotechnology is on the cusp of completing patient dosing in its pivotal Phase III CBD insomnia trial, backed by a recent $2.5 million capital raise and patent allowances in the US and Europe.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Little Green Pharma welcomes a landmark US Executive Order directing cannabis rescheduling, a move poised to reshape the global medicinal cannabis landscape.

Regis Healthcare announces the resignation of CEO Dr Linda Mellors after six years, with a transition period underway as the board searches for her successor.

Aumake Limited has obtained a Hong Kong pharmaceutical wholesale licence, enabling it to launch up to five online over-the-counter medicine stores targeting Chinese consumers. This strategic move positions the company to tap into China’s rapidly expanding OTC market.

Avecho Biotechnology has received patent allowances in the US and Europe for its proprietary CBD soft-gel formulation, reinforcing its intellectual property ahead of pivotal Phase III insomnia trial results expected in mid-2026.

Cann Group Limited has announced a dramatic 81% reduction in core debt alongside a strategic pivot to higher-margin flower products, positioning the company for its first EBITDA-positive year in FY26.

Ryman Healthcare reports a significant financial turnaround with its first positive free cash flow in over ten years, alongside upgraded sales and cost-saving targets for FY26 and completion of a major NZD 2 billion refinancing.